Suppliers and packagers for generic pharmaceutical drug: acarbose

acarbose

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avet Lifesciences	ACARBOSE	acarbose	TABLET;ORAL	202271	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-147-01	100 TABLET in 1 BOTTLE (23155-147-01)	2021-04-16
Avet Lifesciences	ACARBOSE	acarbose	TABLET;ORAL	202271	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-147-05	500 TABLET in 1 BOTTLE (23155-147-05)	2021-04-16
Avet Lifesciences	ACARBOSE	acarbose	TABLET;ORAL	202271	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-147-10	1000 TABLET in 1 BOTTLE (23155-147-10)	2021-04-16

Acarbose Drug Supply Landscape: Key Manufacturers and Patent Expirations

Last updated: February 19, 2026

Acarbose, an alpha-glucosidase inhibitor used to manage type 2 diabetes, faces a dynamic supply and patent landscape. Major generic manufacturers dominate the market, with several key patents having expired, opening avenues for broader competition. Analysis of patent filings, manufacturing capabilities, and market entry strategies reveals opportunities and risks for stakeholders.

Who are the primary manufacturers of acarbose active pharmaceutical ingredients (APIs)?

The production of acarbose API is concentrated among a few established pharmaceutical ingredient manufacturers. These companies possess the specialized chemical synthesis capabilities and regulatory compliance required for pharmaceutical-grade production. Key players include:

• Bayer AG: As the originator of acarbose (marketed as Glucobay/Precose), Bayer maintains significant manufacturing capacity and quality control standards. While its originator patent has long expired, Bayer continues to be a substantial supplier.
• Hetero Drugs Limited: A prominent Indian pharmaceutical company, Hetero is a significant producer of various APIs, including acarbose. Its large-scale manufacturing infrastructure allows for competitive pricing.
• Dr. Reddy's Laboratories: Another major Indian pharmaceutical player, Dr. Reddy's also manufactures acarbose API. The company has a broad portfolio of generic drugs and a robust global distribution network.
• Sun Pharmaceutical Industries Ltd.: Sun Pharma, one of the world's largest generic pharmaceutical companies, is also involved in acarbose API production. Its extensive manufacturing footprint supports its global market presence.
• Divi's Laboratories: Known for its custom synthesis and API manufacturing, Divi's Laboratories is a potential supplier, often serving other major pharmaceutical companies.

These manufacturers adhere to Good Manufacturing Practices (GMP) and have secured approvals from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the key patent expirations impacting acarbose?

The patent landscape for acarbose has significantly evolved, with the expiration of primary composition of matter patents and subsequent formulation or use patents. This has paved the way for generic market entry.

• US Patent 4,260,625: This foundational patent, covering the composition of matter for acarbose, expired in 2005. This marked the initial critical point for generic competition in the United States.
• European Patent EP0003799B1: The corresponding European patent for acarbose also expired, allowing for generic market entry across European Union member states. Expiration dates vary by country due to national validation and potential extensions, but the core patent protection ceased in the early to mid-2000s.
• Formulation Patents: Subsequent patents covering specific formulations, dosages, or combinations of acarbose have also expired or are nearing expiration. For instance, patents related to extended-release formulations or specific synergistic combinations with other antidiabetic agents would have provided periods of extended market exclusivity for those specific product types.
• Method of Treatment Patents: Patents claiming specific methods of treating diabetes or other conditions with acarbose have also seen their exclusivity periods lapse.

The absence of strong, overarching composition of matter patents means that the market is largely driven by the availability of bioequivalent generic products.

What is the current market size and projected growth for acarbose?

The global acarbose market is substantial, driven by the widespread prevalence of type 2 diabetes. While it is a mature drug, its affordability and efficacy in certain patient populations ensure continued demand.

• Market Size: The global acarbose market was valued at approximately USD 650 million in 2022. (Source: Various market research reports)
• Projected Growth: The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to 4.5% from 2023 to 2028. This moderate growth is influenced by:
  • Increasing diabetes prevalence globally, particularly in emerging economies.
  • The cost-effectiveness of acarbose compared to newer antidiabetic agents.
  • The continued availability of generic versions, making it accessible.
  • Competition from newer drug classes with different mechanisms of action and potentially better side-effect profiles.

The demand is robust in regions with a high burden of diabetes, such as Asia-Pacific, and in markets with established healthcare systems that prioritize cost-effective treatments.

Which regulatory bodies have approved acarbose and its generic versions?

Acarbose and its generic formulations have received approval from major global regulatory agencies, facilitating widespread market access.

• U.S. Food and Drug Administration (FDA): The FDA has approved numerous generic acarbose tablets. The approval process requires demonstrating bioequivalence to the reference listed drug (RLD), typically by proving comparable pharmacokinetic profiles.
• European Medicines Agency (EMA) and National Competent Authorities: Acarbose is approved for marketing across the European Union. Generic applications are reviewed by national authorities based on EMA guidelines.
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan: Acarbose is available in Japan, with approvals granted by the PMDA.
• Therapeutic Goods Administration (TGA), Australia: The TGA has approved acarbose products for the Australian market.
• Other National Regulatory Authorities: Approvals are also held by agencies in Canada, Brazil, India, and numerous other countries, reflecting acarbose's global use.

The extensive regulatory approvals underscore the drug's established safety and efficacy profile.

What are the key therapeutic indications and dosage forms for acarbose?

Acarbose is primarily indicated for the management of type 2 diabetes mellitus, acting as an adjunct to diet and exercise. Its mechanism of action targets postprandial hyperglycemia.

• Primary Indication: Management of type 2 diabetes mellitus.
• Mechanism of Action: Acarbose inhibits alpha-glucosidase enzymes in the brush border of the small intestine. These enzymes are responsible for breaking down complex carbohydrates into absorbable monosaccharides. By inhibiting them, acarbose delays carbohydrate digestion and absorption, leading to a reduction in postprandial blood glucose levels.
• Dosage Forms:
  • Oral Tablets: This is the most common dosage form. Typical strengths include 25 mg, 50 mg, and 100 mg.
  • Extended-Release (ER) Formulations: Some markets offer extended-release versions, designed to provide a smoother glucose-lowering effect and potentially reduce gastrointestinal side effects.
• Typical Dosing Regimen: Dosing usually starts at 25 mg three times daily and is gradually increased to 50 mg or 100 mg three times daily, depending on patient tolerance and glycemic control. The dose is taken with the first bite of each main meal.

What are the main challenges and opportunities in the acarbose supply chain?

The acarbose market presents both challenges for established players and opportunities for new entrants or those looking to optimize their supply chain.

Challenges:

• Intense Generic Competition: With most major patents expired, the market is highly competitive, leading to price erosion and pressure on profit margins.
• Regulatory Hurdles for New Entrants: While patents may have expired, obtaining regulatory approvals in key markets requires significant investment in quality control, manufacturing validation, and bioequivalence studies.
• Supply Chain Vulnerabilities: Reliance on specific raw material suppliers or manufacturing sites can create risks related to geopolitical instability, quality control issues, or natural disasters.
• Competition from Newer Drug Classes: The development of newer antidiabetic medications (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) with different mechanisms and perceived advantages (e.g., cardiovascular benefits, weight loss) poses a competitive threat.
• Gastrointestinal Side Effects: Common side effects such as flatulence, diarrhea, and abdominal pain can limit patient adherence and physician preference for acarbose over alternatives.

Opportunities:

• Emerging Markets: The rising prevalence of diabetes in developing countries in Asia, Africa, and Latin America creates significant demand for affordable antidiabetic medications like acarbose.
• Cost-Effective Treatment Options: As healthcare systems globally face cost pressures, acarbose remains an attractive, low-cost treatment option, particularly for large patient populations.
• API Manufacturing Optimization: Companies with efficient and cost-effective API manufacturing processes can gain a competitive advantage by offering competitive pricing for generic formulations.
• Supply Chain Integration: Vertical integration, from API production to finished dosage forms, can enhance control over quality, cost, and supply reliability.
• Specialty Formulations: Development of improved formulations (e.g., improved palatability, reduced GI side effects, once-daily dosing) could create niche market opportunities, although patent protection for such innovations would need to be robust and distinct from expired core patents.
• Contract Manufacturing: Opportunities exist for contract manufacturing organizations (CMOs) to produce acarbose API or finished dosage forms for generic companies that lack in-house manufacturing capabilities.

What is the future outlook for acarbose manufacturers and suppliers?

The future outlook for acarbose manufacturers and suppliers is characterized by a focus on cost efficiency, market access, and navigating a competitive landscape.

• Dominance of Generic Players: Generic manufacturers will continue to dominate the market. Success will hinge on economies of scale, efficient supply chain management, and strong distribution networks.
• Focus on Emerging Markets: Growth will be increasingly driven by demand in emerging economies where affordability is a primary concern. Manufacturers with established presence and distribution channels in these regions will have an advantage.
• API Cost Sensitivity: The cost of API production will remain a critical determinant of profitability. Manufacturers who can optimize synthesis routes and secure stable, cost-effective raw material supplies will thrive.
• Regulatory Compliance: Continuous adherence to evolving GMP standards and maintaining regulatory approvals in diverse global markets will be essential.
• Limited Innovation Potential: While incremental formulation improvements are possible, the potential for significant breakthrough innovations is limited due to the drug's maturity and extensive patent expirations. The focus will remain on optimizing the production and delivery of the existing molecule.
• Strategic Partnerships: Collaborations between API manufacturers and finished dosage form producers, or partnerships for market entry in specific regions, may become more common.

The market for acarbose will remain a significant segment of the antidiabetic drug market, driven by its established role in diabetes management and its cost-effectiveness.

Key Takeaways

• Patent Expirations: Core patents for acarbose have expired, leading to a highly competitive generic market.
• Major API Suppliers: Key manufacturers of acarbose API include Bayer, Hetero Drugs, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries.
• Market Size and Growth: The global acarbose market is valued at approximately $650 million and is projected to grow at a CAGR of 3.5%-4.5% annually.
• Regulatory Approvals: Acarbose and its generics are approved by major regulatory bodies including the FDA, EMA, and PMDA.
• Therapeutic Use: Primarily used to manage type 2 diabetes by inhibiting alpha-glucosidase enzymes.
• Challenges & Opportunities: Intense price competition and newer drug classes are challenges, while emerging markets and cost-effective solutions present opportunities.
• Future Outlook: Manufacturers will focus on cost efficiency, market access in emerging economies, and robust regulatory compliance.

FAQs

1. What is the typical patent expiration date for acarbose formulations beyond the initial composition of matter patent?

Beyond the composition of matter patent (U.S. Patent 4,260,625, expired 2005), patents covering specific formulations, such as extended-release versions, typically provided exclusivity for a period of 17 years from their grant date, or potentially longer if patent term restoration was applied. These formulation patents have also largely expired or are nearing the end of their term, further contributing to generic market saturation. For example, patents related to specific extended-release technologies might have expired between 2010 and 2020, depending on their grant dates.

2. How does the manufacturing cost of acarbose API compare to that of newer antidiabetic drugs like GLP-1 receptor agonists?

The manufacturing cost of acarbose API is significantly lower than that of newer antidiabetic drugs such as GLP-1 receptor agonists. Acarbose is a relatively simple small molecule synthesized through established chemical processes. In contrast, GLP-1 receptor agonists are complex peptide-based drugs, often produced via recombinant DNA technology or complex peptide synthesis, which are inherently more expensive and require more sophisticated manufacturing infrastructure and quality control. This cost differential is a primary driver for acarbose's continued use in cost-sensitive markets.

3. Are there any significant ongoing patent disputes or litigation related to acarbose?

Due to the maturity of acarbose and the expiration of its core patents, significant ongoing patent disputes or litigation are unlikely to be a major factor in the current market. Most patent challenges would have occurred during the period of patent protection. Any remaining litigation would likely pertain to very specific, niche formulation patents or potential process patents, which are less impactful on the broad generic market compared to composition of matter patents.

4. What is the role of pharmacoeconomic data in the continued use of acarbose?

Pharmacoeconomic data plays a crucial role in the sustained use of acarbose. As a low-cost medication, acarbose demonstrates favorable cost-effectiveness ratios when compared to newer, more expensive antidiabetic agents, particularly in patient populations where its efficacy is well-established. Studies often highlight the cost per unit of glycemic control (e.g., cost per HbA1c reduction) achieved with acarbose, making it an attractive option for healthcare systems facing budget constraints and aiming to provide access to treatment for a large number of diabetic patients.

5. What are the primary API sourcing considerations for generic drug manufacturers looking to enter or expand in the acarbose market?

For generic drug manufacturers, primary API sourcing considerations for acarbose include:

• API Quality and Regulatory Compliance: Ensuring the API supplier is GMP-certified and has a strong regulatory history with relevant health authorities (FDA, EMA). This includes having Drug Master Files (DMFs) readily available.
• Cost Competitiveness: Negotiating favorable pricing for the API is critical given the price-sensitive nature of the generic acarbose market.
• Supply Chain Reliability and Security: Assessing the supplier's capacity, lead times, and their ability to ensure consistent supply, mitigating risks of shortages due to unforeseen events.
• Technical Support: The availability of technical support from the API manufacturer for process validation, impurity profiling, and troubleshooting is important.
• Geographic Diversification: Sourcing from multiple suppliers or suppliers with diverse manufacturing locations can mitigate geopolitical or logistical risks.

---

Citations

[1] Various market research reports on the global acarbose market. (Accessed October 2023). [2] U.S. Patent 4,260,625. (Granted 1981, Expired 2005). [3] European Patent EP0003799B1. (Date of grant and expiration vary by national validation, core patent protection expired in early to mid-2000s).